Research Analysts’ Recent Ratings Updates for Rhythm Pharmaceuticals (RYTM)

A number of firms have modified their ratings and price targets on shares of Rhythm Pharmaceuticals (NASDAQ: RYTM) recently:

• 3/3/2026 – Rhythm Pharmaceuticals had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $125.00 price target on the stock.
• 3/2/2026 – Rhythm Pharmaceuticals had its price target lowered by Canaccord Genuity Group Inc. from $141.00 to $140.00. They now have a “buy” rating on the stock.
• 3/2/2026 – Rhythm Pharmaceuticals had its price target lowered by HC Wainwright from $125.00 to $110.00. They now have a “buy” rating on the stock.
• 2/27/2026 – Rhythm Pharmaceuticals had its price target lowered by Wells Fargo & Company from $145.00 to $136.00. They now have an “overweight” rating on the stock.
• 2/27/2026 – Rhythm Pharmaceuticals had its price target raised by Citizens Jmp from $167.00 to $176.00. They now have a “market outperform” rating on the stock.
• 2/27/2026 – Rhythm Pharmaceuticals had its price target raised by Guggenheim from $140.00 to $143.00. They now have a “buy” rating on the stock.
• 2/26/2026 – Rhythm Pharmaceuticals was given a new $131.00 price target by Stifel Nicolaus.
• 2/26/2026 – Rhythm Pharmaceuticals had its price target lowered by Needham & Company LLC from $148.00 to $139.00. They now have a “buy” rating on the stock.
• 2/18/2026 – Rhythm Pharmaceuticals is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $145.00 price target on the stock.
• 2/18/2026 – Rhythm Pharmaceuticals is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $145.00 price target on the stock.
• 2/18/2026 – Rhythm Pharmaceuticals was upgraded by Royal Bank Of Canada to “moderate buy”.
• 2/17/2026 – Rhythm Pharmaceuticals was upgraded by Zacks Research from “strong sell” to “hold”.
• 1/22/2026 – Rhythm Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 1/20/2026 – Rhythm Pharmaceuticals had its price target raised by HC Wainwright from $123.00 to $125.00. They now have a “buy” rating on the stock.
• 1/20/2026 – Rhythm Pharmaceuticals had its price target raised by Wells Fargo & Company from $129.00 to $145.00. They now have an “overweight” rating on the stock.
• 1/19/2026 – Rhythm Pharmaceuticals was downgraded by Zacks Research from “hold” to “strong sell”.

Insider Activity

In other news, CFO Hunter C. Smith sold 4,385 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $101.26, for a total value of $444,025.10. Following the completion of the transaction, the chief financial officer owned 110,512 shares of the company’s stock, valued at approximately $11,190,445.12. This trade represents a 3.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Christopher Paul German sold 5,614 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $89.56, for a total transaction of $502,789.84. Following the sale, the chief accounting officer directly owned 160 shares in the company, valued at approximately $14,329.60. The trade was a 97.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 27,267 shares of company stock worth $2,719,955. 6.10% of the stock is owned by corporate insiders.

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.